American Century Companies Reduces Vertex Pharmaceuticals Stake

Investment firm cuts position in biotech company by 16.5% in Q3

Mar. 3, 2026 at 1:39am

Got story updates? Submit your updates here. ›

American Century Companies Inc. reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 16.5% in the third quarter, according to a recent SEC filing. The investment firm now owns 449,193 shares of the pharmaceutical company's stock, down from 538,132 shares previously.

Why it matters

Vertex Pharmaceuticals is a leading biotech company focused on developing treatments for serious diseases like cystic fibrosis. Changes in institutional ownership of the stock can signal shifts in investor sentiment and future performance expectations.

The details

According to the SEC filing, American Century Companies sold 88,939 shares of Vertex Pharmaceuticals during the third quarter. The firm now owns approximately 0.18% of Vertex's outstanding shares, down from 0.21% previously. Several other large investors, including Vanguard Group and Geode Capital Management, also hold significant positions in Vertex Pharmaceuticals.

  • The SEC filing was made on March 1, 2026, covering the third quarter of 2025.

The players

American Century Companies Inc.

An investment management firm based in Kansas City, Missouri that oversees over $200 billion in assets.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing treatments for serious diseases like cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

The reduction in American Century's Vertex Pharmaceuticals stake suggests a potential shift in investor sentiment around the biotech company, though the overall outlook remains positive with strong institutional ownership and analyst coverage.